Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2026)

Amneal Pharmaceuticals' Short term Debt history runs 10 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Short term Debt fell 80.5% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 80.5% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 96.98% from the prior year.
• Short term Debt retreated to $6.2 million in Q1 2026 per AMRX's latest filing, from $6.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $290.0 million in Q2 2025 and bottomed at $6.2 million in Q1 2026.
• The 5-year median for Short term Debt is $30.5 million (2023), against an average of $87.1 million.
• Across the five-year window, Short term Debt surged 640.52% in 2024 and plunged 96.98% in 2025, its largest moves.
• Year by year, Short term Debt stood at $30.0 million in 2022, then soared by 497.44% to $179.0 million in 2023, then climbed by 25.26% to $224.2 million in 2024, then plunged by 96.98% to $6.8 million in 2025, then dropped by 8.3% to $6.2 million in 2026.
• Per Business Quant, the three latest AMRX Short term Debt figures stand at $6.2 million (Q1 2026), $6.8 million (Q4 2025), and $7.2 million (Q3 2025).